
    
      The study is a single center,open label trial. To obtain safety information on toxicities and
      adverse events attributable to the subcutaneous injections of autologous dendritic cells
      incubated with irradiated autologous tumor stem cells and suspended in GM-CSF in patients
      with HCC.
    
  